Cargando…

Primary tumour immune response and lymph node yields in colon cancer

BACKGROUND: The mechanism underlying improved survival in non-metastatic colon cancer with higher lymph node (LN) yield is unknown. This study aimed to identify whether molecular features in the primary tumour were predictive of LN yield. METHODS: Clinical, genomic, transcriptomic, proteomic and met...

Descripción completa

Detalles Bibliográficos
Autores principales: Lal, Nikhil, Chan, Dedrick Kok Hong, Ng, Minn E, Vermeulen, Louis, Buczacki, Simon James Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9023574/
https://www.ncbi.nlm.nih.gov/pubmed/35043009
http://dx.doi.org/10.1038/s41416-022-01700-1
_version_ 1784690379076927488
author Lal, Nikhil
Chan, Dedrick Kok Hong
Ng, Minn E
Vermeulen, Louis
Buczacki, Simon James Alexander
author_facet Lal, Nikhil
Chan, Dedrick Kok Hong
Ng, Minn E
Vermeulen, Louis
Buczacki, Simon James Alexander
author_sort Lal, Nikhil
collection PubMed
description BACKGROUND: The mechanism underlying improved survival in non-metastatic colon cancer with higher lymph node (LN) yield is unknown. This study aimed to identify whether molecular features in the primary tumour were predictive of LN yield. METHODS: Clinical, genomic, transcriptomic, proteomic and methylation data of non-metastatic, colon cancers studied in The Cancer Genome Atlas were interrogated for associations with LN yield. Based on maximal survival effects, patients were segregated into high (>15) and low (≤15) LN yield. Gene set enrichment analysis was performed on transcriptomic changes to identify biological processes associated with LN yield. Correlations were validated in an independent set of Stage II colon cancers. RESULTS: High LN yield was found predictive of overall and disease-free survival. There was no association of higher LN yield and increasing nodal positivity. High LN yield was strongly linked with gene expression changes associated with the adaptive and dendritic cell immune response. This association was most prominent in node-negative cancers. Analogous findings were reproduced in the validation dataset. CONCLUSION: The study shows a strong association of an activated immune response in tumours with a high LN yield. Immunogenic tumours have a better prognosis, likely explaining the survival benefit with higher LN yields.
format Online
Article
Text
id pubmed-9023574
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-90235742022-04-28 Primary tumour immune response and lymph node yields in colon cancer Lal, Nikhil Chan, Dedrick Kok Hong Ng, Minn E Vermeulen, Louis Buczacki, Simon James Alexander Br J Cancer Article BACKGROUND: The mechanism underlying improved survival in non-metastatic colon cancer with higher lymph node (LN) yield is unknown. This study aimed to identify whether molecular features in the primary tumour were predictive of LN yield. METHODS: Clinical, genomic, transcriptomic, proteomic and methylation data of non-metastatic, colon cancers studied in The Cancer Genome Atlas were interrogated for associations with LN yield. Based on maximal survival effects, patients were segregated into high (>15) and low (≤15) LN yield. Gene set enrichment analysis was performed on transcriptomic changes to identify biological processes associated with LN yield. Correlations were validated in an independent set of Stage II colon cancers. RESULTS: High LN yield was found predictive of overall and disease-free survival. There was no association of higher LN yield and increasing nodal positivity. High LN yield was strongly linked with gene expression changes associated with the adaptive and dendritic cell immune response. This association was most prominent in node-negative cancers. Analogous findings were reproduced in the validation dataset. CONCLUSION: The study shows a strong association of an activated immune response in tumours with a high LN yield. Immunogenic tumours have a better prognosis, likely explaining the survival benefit with higher LN yields. Nature Publishing Group UK 2022-01-18 2022-05-03 /pmc/articles/PMC9023574/ /pubmed/35043009 http://dx.doi.org/10.1038/s41416-022-01700-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Lal, Nikhil
Chan, Dedrick Kok Hong
Ng, Minn E
Vermeulen, Louis
Buczacki, Simon James Alexander
Primary tumour immune response and lymph node yields in colon cancer
title Primary tumour immune response and lymph node yields in colon cancer
title_full Primary tumour immune response and lymph node yields in colon cancer
title_fullStr Primary tumour immune response and lymph node yields in colon cancer
title_full_unstemmed Primary tumour immune response and lymph node yields in colon cancer
title_short Primary tumour immune response and lymph node yields in colon cancer
title_sort primary tumour immune response and lymph node yields in colon cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9023574/
https://www.ncbi.nlm.nih.gov/pubmed/35043009
http://dx.doi.org/10.1038/s41416-022-01700-1
work_keys_str_mv AT lalnikhil primarytumourimmuneresponseandlymphnodeyieldsincoloncancer
AT chandedrickkokhong primarytumourimmuneresponseandlymphnodeyieldsincoloncancer
AT ngminne primarytumourimmuneresponseandlymphnodeyieldsincoloncancer
AT vermeulenlouis primarytumourimmuneresponseandlymphnodeyieldsincoloncancer
AT buczackisimonjamesalexander primarytumourimmuneresponseandlymphnodeyieldsincoloncancer